ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Other analysts have also issued research reports about the stock. HC Wainwright initiated coverage on shares of ZIOPHARM Oncology in a research report on Thursday, June 1st. They set a “buy” rating and a $9.50 price target on the stock. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, April 26th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. ZIOPHARM Oncology presently has a consensus rating of “Hold” and a consensus price target of $13.17.

ZIOPHARM Oncology (ZIOP) remained flat at $5.51 on Monday. 1,003,534 shares of the company’s stock traded hands. The stock’s 50 day moving average is $5.91 and its 200 day moving average is $6.34. ZIOPHARM Oncology has a 12 month low of $4.84 and a 12 month high of $7.88. The stock’s market capitalization is $774.88 million.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. The firm’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.01) EPS. On average, analysts predict that ZIOPHARM Oncology will post ($0.54) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Rating Lowered to Sell at BidaskClub” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/14/ziopharm-oncology-inc-nasdaqziop-rating-lowered-to-sell-at-bidaskclub.html.

Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in shares of ZIOPHARM Oncology by 18.4% in the fourth quarter. Wells Fargo & Company MN now owns 168,616 shares of the biotechnology company’s stock valued at $1,402,000 after buying an additional 26,233 shares during the period. Morgan Stanley raised its stake in shares of ZIOPHARM Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 78,583 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ZIOPHARM Oncology by 5.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 603,844 shares of the biotechnology company’s stock valued at $5,018,000 after buying an additional 28,576 shares during the period. Third Security LLC raised its stake in shares of ZIOPHARM Oncology by 0.3% in the fourth quarter. Third Security LLC now owns 9,692,403 shares of the biotechnology company’s stock valued at $80,544,000 after buying an additional 26,661 shares during the period. Finally, Capital Fund Management S.A. bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter valued at about $348,000. Institutional investors and hedge funds own 38.17% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.